RNAi and pharmacological inhibitors have also been used to target GSDMD-mediated inflammation in non-ocular tissues, these include Necrosulfonamide [86], LDC7559 [87], Disulfiram [88] and Dimethyl fumarate (DMF) [89], C202-2729 [90], all of which have been demonstrated to impair GSDMD function but also have off target effects and have not been approved for use in retinal degenerations. This evidence concerns the gene GSDMD and retinal degeneration.